Adjuvant Capital
Finance · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
501 5th Ave Rm 1404, New York City, New ...Phone Number
(917) 334-0724Website
www.adjuvantcapital.comRevenue
$6 MillionIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
1
2
1
2
About Adjuvant Capital
Adjuvant Capital is a venture capital firm focused on financing innovative life science technologies that address high-burden public health challenges. The company invests in areas such as infectious diseases, maternal and child health, and nutrition, aiming to make impactful medical innovations accessible to underserved populations. With a unique investment model influenced by global trends, Adjuvant targets innovations that promise significant health outcomes in emerging markets. Their approach differentiates them from traditional venture capital firms by emphasizing both social and financial returns for their investors.Explore more
Adjuvant Capital Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Adjuvant Capital your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Adjuvant Capital, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Adjuvant Capital has new funding data
Congratulate Masked Content for being promoted to Masked Content at Adjuvant Capital
Check if Adjuvant Capital has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Adjuvant Capital launches new products
Check out if Adjuvant Capital is spiking on competitors!
Earning: See what the market has to say on Adjuvant Capital recently announced quarterly report
Click to see if Adjuvant Capital had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Adjuvant Capital
Find 3 more new buyers
Compare Similar Companies to Adjuvant Capital
Compare insights from companies similar to Adjuvant Capital, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Adjuvant Capital is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Adjuvant Capital is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Adjuvant Capital.
Adjuvant Capital Tech Stack
A closer look at the technologies used by Adjuvant Capital
Most Recent Scoops
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Adjuvant Capital News & Media
Memo Therapeutics Raises CHF 20M; Increases Series C to CHF 45M
Memo Therapeutics, a Schlieren, Zurich, Switzerland-based late-stage biotech company developing a BKV-neutralizing antibody for BKV infection in kidney transplantation, raised additional CHF 20M bringing the total amount of its Series C to CHF 45M. New investors Ysios Capital and Kurma Partners participated in the extension round, joining existing Series C round investors including Pureos Bioventures, […] The post Memo Therapeutics Raises CHF 20M; Increases Series C to CHF 45M appeared first onMemo Therapeutics Raises CHF 25M in Series C Financing
Memo Therapeutics, a Schlieren / Zurich, Switzerland-based late-stage biotech company, raised CHF 25M in Series C funding. The round was led by Pureos Bioventures, with participation from xisting investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group, Fresenius Medical Care Ventures and Red Alpine. The company intends to use the funds to complete U.S. Phase II […] The post Memo Therapeutics Raises CHF 25M in Series C Financing appeared first on FLimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections
SCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorrAntiva Biosciences Closes $53M Series E Equity Financing
Antiva Biosciences, a South San Francisco, CA-based biopharmaceutical company developing topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, raised $53M in Series E funding. The round was led by MPM-BioImpact Capital, and joined by existing investors including Canaan Partners, Sofinnova Investments, Adjuvant Capital, GV and Lumira Ventures, among others. The company […] The post Antiva Biosciences Closes $53M Series E Equity Financing
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Adjuvant Capital
Sign Up For FreeTo access detailed company insights
Adjuvant Capital is a venture capital firm focused on financing innovative life science technologies that address high-burden public health challenges. The company invests in areas such as infectious diseases, maternal and child health, and nutrition, aiming to make impactful medical innovations accessible to underserved populations. With a unique... Read More
